Skip to main content

Table 2 Patient characteristics a

From: Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

  Offered incentive (N = 481) Not offered incentive (N = 534)
Age (mean, SD) 66.2 (10.2) 66.3 (9.6)
Sex   
 Male 281 (58.4) 308 (57.7)
 Female 162 (33.7) 182 (34.1)
 Unknown 38 (7.9) 44 (8.2)
SIMD deprivation categoryb   
 1–3 (least deprived) 138 (28.7) 134 (25.1)
 4–7 242 (50.3) 274 (51.4)
 8–10 (most deprived) 101 (21.0) 125 (23.5)
Geographic areasb   
 Angus and Dundee 217 (45.1) 215 (40.3)
 Fife 200 (41.6) 234 (43.9)
 Perth 64 (13.3) 84 (15.8)
Target patient group   
 FAST 158 (32.9) 174 (32.6)
 SCOT 84 (17.5) 97 (18.2)
 PATHWAY 1 46 (9.6) 47 (8.8)
 PATHWAY 2 101 (21.0) 109 (20.4)
 PATHWAY 3 92 (19.1) 107 (20.0)
  1. aFAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial; SIMD, SD, Standard deviation; Scottish Index of Multiple Deprivation. Data are mean (SD) or number (%). There were no significant differences between groups bIncludes one patient with missing data.